CONDENSED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenue:
Genetic testing	$ 140,638	$ 262,469
Other	55,806	698,449
Total revenue	196,444	960,918
Cost of revenue	309,876	526,946
Gross (loss) profit	(113,432)	433,972
Operating expenses:
Research and development	424,591	480,057
Selling, general and administrative	1,769,773	1,311,185
Amortization of intangibles	4,780	8,362
Total operating expenses	2,199,144	1,799,604
Loss from operations	(2,312,576)	(1,365,632)
Other expense:
Interest expense	(108,373)	(113,750)
Interest expense non-cash	(108,761)	(38,354)
Total other expense	(217,134)	(152,104)
Loss before income taxes	(2,529,710)	(1,517,736)
Benefit from income taxes	0	0
Net loss	$ (2,529,710)	$ (1,517,736)
Basic and diluted net loss per common share	$ (0.01)	$ (0.01)
Weighted average common shares outstanding, basic and diluted	229,434,511	172,951,968